Sentences with phrase «rate than other technologies»

E Ink has upped the resolution of their 6 - inch screens from 800 x 600 to 1024 x 758 over the past couple of years, and the Kobo Aura HD has a unique 1440 x 1080 6.8 - inch Pearl screen, but overall E Ink advances at a slower rate than other technologies, and color E Ink has still yet to become effective enough to really take off.

Not exact matches

These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.

Among the factors that could cause actual results to differ materially are the following: (1) worldwide economic, political, and capital markets conditions and other factors beyond the Company's control, including natural and other disasters or climate change affecting the operations of the Company or its customers and suppliers; (2) the Company's credit ratings and its cost of capital; (3) competitive conditions and customer preferences; (4) foreign currency exchange rates and fluctuations in those rates; (5) the timing and market acceptance of new product offerings; (6) the availability and cost of purchased components, compounds, raw materials and energy (including oil and natural gas and their derivatives) due to shortages, increased demand or supply interruptions (including those caused by natural and other disasters and other events); (7) the impact of acquisitions, strategic alliances, divestitures, and other unusual events resulting from portfolio management actions and other evolving business strategies, and possible organizational restructuring; (8) generating fewer productivity improvements than estimated; (9) unanticipated problems or delays with the phased implementation of a global enterprise resource planning (ERP) system, or security breaches and other disruptions to the Company's information technology infrastructure; (10) financial market risks that may affect the Company's funding obligations under defined benefit pension and postretirement plans; and (11) legal proceedings, including significant developments that could occur in the legal and regulatory proceedings described in the Company's Annual Report on Form 10 - K for the year ended Dec. 31, 2017, and any subsequent quarterly reports on Form 10 - Q (the «Reports»).

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Other winners include telecommunications, media and technology bankers and traders of rates options and equity derivatives — all getting 15 percent more than last year.

These risks and uncertainties include food safety and food - borne illness concerns; litigation; unfavorable publicity; federal, state and local regulation of our business including health care reform, labor and insurance costs; technology failures; failure to execute a business continuity plan following a disaster; health concerns including virus outbreaks; the intensely competitive nature of the restaurant industry; factors impacting our ability to drive sales growth; the impact of indebtedness we incurred in the RARE acquisition; our plans to expand our newer brands like Bahama Breeze and Seasons 52; our ability to successfully integrate Eddie V's restaurant operations; a lack of suitable new restaurant locations; higher - than - anticipated costs to open, close or remodel restaurants; increased advertising and marketing costs; a failure to develop and recruit effective leaders; the price and availability of key food products and utilities; shortages or interruptions in the delivery of food and other products; volatility in the market value of derivatives; general macroeconomic factors, including unemployment and interest rates; disruptions in the financial markets; risk of doing business with franchisees and vendors in foreign markets; failure to protect our service marks or other intellectual property; a possible impairment in the carrying value of our goodwill or other intangible assets; a failure of our internal controls over financial reporting or changes in accounting standards; and other factors and uncertainties discussed from time to time in reports filed by Darden with the Securities and Exchange Commission.

The dropout rate and graduation rate do not total 100 percent because some students complete high school through means other than a high school diploma (e.g., students with a GED, students with disabilities who have participated in alternative assessment, or students who have transferred into higher education or an applied technology college without graduating high school) and some special education students are retained in high school beyond their senior year.

Kia Motors Australia COO, Damien Meredith, said: «At no stage was there any suggestion that the physical crash safety of any Stinger model was less than any other grade, however the absence of some technology on the entry - level cars led to a split rating.

These are a few reasons why we sell more pre-owned vehicles than any other dealer in Northwest Missouri.Awards: * Green Car Journal Green Car Technology Award * NACTOY North American Truck of the Year * 2015 KBB.com Brand Image AwardsBased on 2017 EPA mileage ratings.

There aren't any measured quantitative specs that help evaluate display performance in high ambient lighting other than the DisplayMate Contrast Rating for High Ambient Light values that are included in all of our Mobile Display Technology Shoot - Out articles.

Smartphones and tablets are being adopted at faster rates than almost every other major technology shift in history, while retail space for physical media continues to shrink.

OLED displays are brighter, more efficient, thinner and feature better refresh rates and contrast than other display technologies.

Other countries are utilizing green water technologies at a much higher rate than the United States.

Solar has surpassed a variety of milestones — for example, utility scale solar is growing at a rate faster than other generation technologies, wind and solar provided over 10 % of U.S. power in March, and utility scale solar has already broke the $ 1 / watt pricing goal set up by the U.S. DOE.

Standard & Poor's (S&P) has lauded the early performance of the solar assets it rates, ultimately concluding that operational risk in solar is «more benign» than other renewable technologies.

Though these and other safety features will certainly keep your family safer, unfortunately they won't lower your insurance rate: our latest research found that despite proven safety benefits, new technology saves drivers less than 1 % a year on their car insurance premiums.

I made more than 3,100 listing presentations in the 1990s at a higher commission rate and here's what happened: 8 percent signed the higher commission rate and longer listing without a quibble; 7 percent OKed one or the other; and another 9 percent signed one or both after a wonderful discussion about my «perceived» superiority in technology, systems, marketing, customer service, team concepts, follow - up, and consistency.

We provide services at a rate that is cheaper than almost any other country at the moment — certainly cheaper than what Realtors to the south are paying for their technology.